ADA-SCID Gene Therapy Endorsed By European Medicines Agency For Marketing Authorization.
Seppo
S
Ylä-Herttuala
D000243:Adenosine Deaminase / Q000172:deficiency* / Q000235:genetics* / Q000378:metabolism; D000361:Agammaglobulinemia / Q000201:enzymology / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D018076:DNA, Complementary / Q000235:genetics / Q000378:metabolism; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D005062:European Union; D015870:Gene Expression; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000737:chemistry / Q000378:metabolism; D006801:Humans; D040541:Marketing / Q000331:legislation & jurisprudence*; D012190:Retroviridae / Q000235:genetics / Q000378:metabolism; D016511:Severe Combined Immunodeficiency / Q000201:enzymology / Q000235:genetics / Q000473:pathology / Q000628:therapy*
D018076:DNA, Complementary; D000243:Adenosine Deaminase